Metastatic breast cancer trials in Spain

In Spain 73 Also abroad 609

73 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 15 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype
Where
A Coruna, A Coruña, Badalona, Barcelona, Bilbao, Cáceres, Girona, Granada, Jaén, Lleida, Madrid, Majadahonda, Málaga, Murcia, Reus, Santiago de Compostela, Sant Joan d'Alacant, Sevilla, Valencia, Zaragoza
Age
18 years and over
People
200 worldwide
Run by
MedSIR
See details and how to joinNCT06486883 · EU 2024-512360-55-00
Phase 1/2Taking people
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Where
Barcelona, Logroño, Madrid, Pozuelo de Alarcón, Reus, Sevilla
Age
18 years and over
People
880 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT05768139 · EU 2023-504807-94-00
Phase 1Taking people
First-in-Human Study of OKI-219 Alone and in Combination with Other Therapies in Patients with Solid Tumors / Breast Cancer
Where
Barcelona, Lleida, Madrid, Pozuelo de Alarcón
Age
18 years and over
People
145 worldwide
Run by
Onkure Inc.
See details and how to join2023-508435-31-00
Phase 2Taking people
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
Where
Madrid
Age
18 years and over
People
37 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT04641247 · EU 2023-506618-29-00
Phase 1/2Taking people
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
Where
Barcelona, Madrid, Usera
Age
18 years and over
People
95 worldwide
Run by
Ellipses Pharma
See details and how to joinNCT05573126
Phase 3Active, not recruiting
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
Where
Barcelona, Donostia, Granada, Las Palmas de Gran Canaria, L'Hospitalet de Llobregat, Madrid, Majadahonda, Murcia, Pamplona, Santiago de Compostela, Sevilla, Valencia
Age
18 years and over
People
250 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT05950945 · EU 2023-505616-38-00
Phase 1/2Taking people
Beamion BCGC-1: A study to find a suitable dose of zongertinib used alone and in combination with other treatments to test whether it helps people with different types of HER2+ cancer that has spread
Where
A Coruña, Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Sevilla, Valencia
Age
18 years and over
People
181 worldwide
Run by
Boehringer Ingelheim International GmbH
See details and how to join2023-509566-38-00
Phase 1/2Taking people
Study of GVV858 as a single agent or in combination with endocrine therapy in patients with HR+/HER2- breast cancer and other advanced solid tumors
Where
Barcelona, Madrid
Age
18 years and over
People
55 worldwide
Run by
Novartis Pharma AG
See details and how to join2025-521911-38-00
Phase 2Taking people
Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer
Where
Barcelona, Bilbao, Granada, Madrid, Málaga, Murcia, Santiago de Compostela, Valencia
Age
18 years to 64 years
People
140 worldwide
Run by
Queen Mary University of London
See details and how to joinNCT06954480 · EU 2024-519913-76-00
Phase 1Taking people
A Phase I Interventional Open-label, Non-randomized Dose-escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Anti-tumor Activity of Autologous p95HER2.CAR-TECH2Me T Cells in Patients With Selected Advanced Cancers.
Where
Barcelona
Age
18 years and over
People
15
Run by
Vall d'Hebron Institute of Oncology
See details and how to joinNCT07593820 · EU 2024-516660-28-01
No phaseTaking people
Impact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer: The Role of the UGT1A1 Gene as a Predictive Biomarker of Therapeutic Response
Where
Granada
Age
18 years and over
People
70
Run by
Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental
See details and how to joinNCT07582887
Phase 1Taking people
Phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-NNS309 in patients with pancreatic, lung, breast and colorectal cancers.
Where
Barcelona, Madrid
Age
18 years and over
People
76 worldwide
Run by
Novartis Pharma AG
See details and how to join2023-510356-23-00
Phase 1/2Taking people
Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer
Where
Badalona, Barcelona, Logroño, Madrid, Málaga, Murcia, Santander, Valencia
Age
18 years and over
People
24
Run by
MedSIR
See details and how to joinNCT07494448 · EU 2025-524613-89-00
Phase 1Taking people
A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
Where
Barcelona, Madrid, Pamplona, Pozuelo de Alarcón, Valencia
Age
18 years and over
People
241 worldwide
Run by
Totus Medicines
See details and how to joinNCT05683418 · EU 2023-505346-26-01
Phase 3Not yet taking people in Spain
A Study to Investigate the Efficacy and Safety of Letrozole SIE Compared With Femara® (Both Combined With the CDK4/6 Inhibitor Ribociclib) in Postmenopausal Women With HR-Positive, HER2-Negative, Inoperable Locally Advanced or Metastatic Breast Cancer
Where
Córdoba, Lleida, Malaga, San Cristóbal de La Laguna, Sant Cugat del Vallès, Valencia
Age
18 years and over
People
300 worldwide
Run by
Rovi Pharmaceuticals Laboratories
See details and how to joinNCT07340658 · EU 2025-524846-85-00
Phase 2Taking people
Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management
Where
A Coruña, Alicante, Badajoz, Barcelona, Bilbao, Girona, Granada, León, L'Hospitalet de Llobregat, Lleida, Madrid, Málaga, Palma, Pamplona, Reus, San Cristobal De La Laguna, Santander, Santiago de Compostela, Sevilla, Valencia, Valladolid, Zaragoza
Age
18 years and over
People
300 worldwide
Run by
SOLTI Breast Cancer Research Group
See details and how to joinNCT07371585 · EU 2025-521805-41-00
Phase 4Taking people
IMPlementing geriatric assessment for dose Optimization of CDK 4/6-inhibitors in older bReasT cAncer patieNTs – a pragmatic randomized-controlled trial (IMPORTANT trial)
Where
Barcelona
Age
65 years and over
People
495 worldwide
Run by
Region Oerebro Laen
See details and how to join2023-506620-87-00
Phase 1/2Taking people
Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors
Where
Barcelona, Madrid
Age
18 years and over
People
43 worldwide
Run by
One-carbon Therapeutics AB
See details and how to joinNCT07151040 · EU 2024-519639-40-00
Phase 1Taking people
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Where
Barcelona, Madrid, Valencia
Age
18 years and over
People
930 worldwide
Run by
Relay Therapeutics, Inc.
See details and how to joinNCT05216432
No phaseTaking people
Patient-Centric Study to Assess the Impact of Genomic Profiling on the Treatment of Patients With Metastatic Breast Cancer in Spain
Where
Barcelona
Age
18 years and over
People
300
Run by
SOLTI Breast Cancer Research Group
See details and how to joinNCT06991946
Phase 3Not yet taking people in Spain
Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients
Where
Barcelona
Age
70 years and over
People
495 worldwide
Run by
Region Örebro County
See details and how to joinNCT06044623
No phaseTaking people
The Impact of Radiotherapy on Oligometastatic Cancer
Where
Albacete, Barcelona, Castellon, Girona, Granada, Lleida, Madrid, Reus, Seville, Terrassa, Valencia, Zaragoza
Age
18 years and over
People
2,000
Run by
Institut Investigacio Sanitaria Pere Virgili
See details and how to joinNCT05933876
Phase 2Taking people
HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan
Where
Badalona, Barcelona, Granada, L'Hospitalet de Llobregat, Madrid, Reus, Seville, Valencia
Age
18 years and over
People
50
Run by
SOLTI Breast Cancer Research Group
See details and how to joinNCT06236269